PriceTargets.com logo

Climb Bio - CLYM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 420.23%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$1.73 As of 12/4/2025 05:00 PM ET
▼ -0.01 (-0.57%)

This chart shows the closing price for CLYM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Climb Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLYM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLYM

Analyst Price Target is $9.00
▲ +420.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Climb Bio in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 420.23% upside from the last price of $1.73.

This chart shows the closing price for CLYM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Climb Bio. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/16/2025BTIG ResearchReiterated RatingBuy ➝ Buy$8.00
10/16/2025William BlairInitiated CoverageOutperform
10/13/2025HC WainwrightInitiated CoverageBuy$9.00
10/13/2025HC WainwrightInitiated CoverageBuy$9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/22/2025BTIG ResearchReiterated RatingBuy ➝ Buy$7.00
8/15/2025Baird R WUpgradeStrong-Buy
8/15/2025Robert W. BairdInitiated CoverageOutperform$9.00
6/6/2025OppenheimerInitiated CoverageOutperform$10.00
5/22/2025BTIG ResearchInitiated CoverageBuy
5/22/2025BTIG ResearchUpgradeStrong-Buy$7.00
12/2/2024Leerink PartnrsUpgradeStrong-Buy
12/2/2024Leerink PartnersInitiated CoverageOutperform$10.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 6 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 5 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Climb Bio logo
Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.
Read More

Today's Range

Now: $1.73
Low: $1.71
High: $1.77

50 Day Range

MA: $1.92
Low: $1.64
High: $2.32

52 Week Range

Now: $1.73
Low: $1.05
High: $3.21

Volume

257,559 shs

Average Volume

333,925 shs

Market Capitalization

$117.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Climb Bio?

The following Wall Street sell-side analysts have issued research reports on Climb Bio in the last twelve months: Baird R W, BTIG Research, HC Wainwright, Oppenheimer Holdings, Inc., Robert W. Baird, Wall Street Zen, Weiss Ratings, and William Blair.
View the latest analyst ratings for CLYM.

What is the current price target for Climb Bio?

0 Wall Street analysts have set twelve-month price targets for Climb Bio in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 420.2%. Oppenheimer Holdings, Inc. has the highest price target set, predicting CLYM will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $8.00 for Climb Bio in the next year.
View the latest price targets for CLYM.

What is the current consensus analyst rating for Climb Bio?

Climb Bio currently has 1 sell rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CLYM.

What other companies compete with Climb Bio?

Other companies that are similar to Climb Bio include Immuneering, CryoPort, Zevra Therapeutics, DBV Technologies and SNDL. Learn More about companies similar to Climb Bio.

How do I contact Climb Bio's investor relations team?

Climb Bio's physical mailing address is 20 William Street Suite 145, Wellesley Hills MA, 02481. The company's listed phone number is 866-857-2596 and its investor relations email address is [email protected]. The official website for Climb Bio is climbbio.com. Learn More about contacing Climb Bio investor relations.